Aubree Ebersole v. Novo Nordisk, Inc.

758 F.3d 917, 22 Wage & Hour Cas.2d (BNA) 1630, 2014 U.S. App. LEXIS 13030, 2014 WL 3361160
CourtCourt of Appeals for the Eighth Circuit
DecidedJuly 10, 2014
Docket13-2160
StatusPublished
Cited by62 cases

This text of 758 F.3d 917 (Aubree Ebersole v. Novo Nordisk, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aubree Ebersole v. Novo Nordisk, Inc., 758 F.3d 917, 22 Wage & Hour Cas.2d (BNA) 1630, 2014 U.S. App. LEXIS 13030, 2014 WL 3361160 (8th Cir. 2014).

Opinion

*921 SMITH, Circuit Judge.

Aubree Ebersole sued her former employer, Novo Nordisk, Inc. (“Novo”), and her former supervisor at Novo, Murty Si-tarama (collectively, “defendants”), alleging that Novo terminated her in violation of the Family and Medical Leave Act (FMLA). The district court 1 granted summary judgment to the defendants. On appeal, Ebersole avers that the district court erred in granting the defendants summary judgment because genuine issues of material fact remain as to Novo’s motivations for terminating her. We affirm.

I. Background

The parties stipulated to most of the facts for the district court’s summary-judgment determination. Novo is a pharmaceutical company that employs sales representatives who market Novo’s products to doctors. Novo hired Ebersole in March 2007 as one of these representatives. Ebersole worked in the Poplar Bluff District, which covered roughly the southern third of Missouri. Novo employed approximately eight to ten representatives in each district, including the Poplar Bluff District (“District”).

Ebersole was diagnosed with rheumatoid arthritis at 15. Her former direct supervisor, Joe Reichard, opined that Ebersole never tried to hide her condition; in fact, coworkers throughout the District knew of her condition. In January 2009, Ebersole contacted Reichard about taking medical leave for arthritis treatment. She eventually took leave from January SO, 2009, until March 6, 2009, when Ebersole’s physician released her to return to work with no restrictions.

While Ebersole was on leave, Novo terminated Reichard’s employment in February 2009. In April 2009, Murty Sitarama became Reichard’s permanent replacement. During Sitarama’s and Ebersole’s first “field ride” together in which they drove for several hours through rural Missouri, Sitarama asked Ebersole about her arthritis and medication. During the conversation, Ebersole felt pressured by Si-tarama into discussing her condition.

Chris Connell, Reichard’s and Sitara-ma’s supervisor, never asked Ebersole directly about her medical condition despite seeing Ebersole on a quarterly basis. Connell did speak with Reichard on a few occasions about Ebersole’s condition, asking, “Why is Aubree on leave?” and “What’s going on with Aubree?” Ebersole discovered Connell’s interest in her medical condition while conversing with Sitara-ma during the initial field ride. Ebersole characterized her conversation with Sitara-ma as follows:

[Her knowledge about Connell’s interest] was based on my conversations with Murty. Murty saying Chris Connell— I’m aware of your medical condition— medical condition and your medical leave, and Chris Connell wants to know if you’re the effective rep or [another rep] is, put together this list and prove who — you know, is it the sick rep or is it the other rep, who is it.

Shortly after Sitarama replaced Reich-ard in April 2009, another representative in the District, Jake Martin, informed Si-tarama that a Houston, Missouri physician had relocated his practice to Joplin, Missouri. Subsequently, another Novo employee informed Sitarama that this particular doctor had actually moved his practice to Joplin one year earlier. Sitarama determined that Martin had falsified a “call” (visit) to this doctor a few months earlier. *922 Sitarama’s examination of the call logs also revealed that Ebersole falsified three calls to this same doctor within the previous six months. Sitarama then investigated these falsified calls throughout the summer.

Novo’s marketing policy and practice includes development of a “call plan” of physicians for its representatives. Representatives may then make sales calls to physicians on the call plan. Ebersole’s call plan consisted of approximately 100 physicians, including the physician who relocated his practice to Joplin. Each time that representatives meet with a physician on their call list to promote a Novo product, Novo instructs the representative to record the meeting as a “call.” Although not defined precisely, Ebersole understood a “call” to mean that she “had a list of practitioners that was [her] responsibility to work with face-to-face and detail those doctors and get them to commit to writing Novo Nordisk products.” Sitarama and Reichard both explained that a call required face-to-face interaction with one of the physicians on the call list. According to Novo policy, representatives were not to record a call when they met with another member of the physician’s staff; the meeting had to be with the physician on the list or it did not constitute a “call.”

Novo policy notwithstanding, Ebersole traveled to this particular doctor’s office in Houston and met with his nurse practitioner instead. She claims that the doctor was unavailable, so she decided to meet with the nurse practitioner because nurse practitioners have the authority to prescribe Novo products as well. Ebersole admits that this nurse practitioner was not on her call list; however, she claims that Reich-ard occasionally allowed her to record these interactions as calls because Eber-sole had to travel so far to the doctor’s office. Reichard acknowledged that Eber-sole’s listing a meeting with a nurse practitioner as “a call” clearly violated Novo policy.

In 2007 and 2009, Ebersole acknowledged that she received, read, and understood a copy of Novo’s Handbook/Code of Conduct (“Code”) that contained Novo’s policies and procedures. The content of the two versions did not differ in any material way. The 2009 Handbook reflected Novo’s policy regarding call falsification, stating:

Falsification or misrepresentation of any Company documents or reports is considered misconduct. Such falsification includes, but is not limited to:
Reporting a call that has not been made or on a date other than that on which the call was actually made;
Reporting a visit to a customer that does not meet the definition of a call (as defined by each Division’s Call Reporting System)!.]

The Handbook also stated that Novo could take “[appropriate disciplinary action, up to and including termination” against an employee who violated Novo policy. Despite the Code’s emphasis on progressive discipline, it also provided that employees were subject to immediate termination for “dishonesty and/or misstatement or falsification of ... company business records.”

Ebersole alleges that Sitarama warned her around July 2009 that she was not to take any more vacation leave that year. The following month, Ebersole requested three vacation days for personal reasons unrelated to her arthritis. Sitarama approved her request; however, the day before Ebersole was to begin this three-day vacation, Sitarama and Connell met with both Ebersole and Martin and terminated them for call falsification. In 2009, Novo fired six other representatives from the District for call falsification. They also *923 fired dozens more representatives throughout the country for the same reason.

Ebersole sued Novo and Sitarama in February 2011, alleging retaliation under the FMLA and violations of the Americans with Disabilities Act.

Related

Cite This Page — Counsel Stack

Bluebook (online)
758 F.3d 917, 22 Wage & Hour Cas.2d (BNA) 1630, 2014 U.S. App. LEXIS 13030, 2014 WL 3361160, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aubree-ebersole-v-novo-nordisk-inc-ca8-2014.